CIMATRON LTD (CIMT) [Rocket]

Overview

CIMATRON LTD (CIMT)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
02/12/2015	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/12/2015	SC 13G/A	Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio reports a 5.3% stake in Cimatron Limited
02/12/2015	SC 13G/A	WELLINGTON TRUST Co N A reports a 6.2% stake in Cimatron Limited
04/30/2014	20-F	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/10/2014	SC 13G	Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio reports a 5.8% stake in Cimatron Limited
02/14/2014	SC 13G/A	Invicta Capital Management, LLC reports a 3.2% stake in Cimatron Ltd.
02/14/2014	SC 13G/A	Invicta Capital Management, LLC reports a 7.6% stake in Cimatron Ltd.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-13	Dec-31-12	Dec-31-11	Dec-31-10	Dec-31-09
Revenues	44.2	42.3	40.7	36.1	33.0
Revenue growth	4.6%	3.9%	12.9%	9.5%
Cost of goods sold	12.2	10.7	11.4	18.1	6.2
Gross profit	32.0	31.6	29.3	17.9	26.8
Gross margin	72.4%	74.8%	72.0%	49.7%	81.2%
Selling, general and administrative	30.5	29.3	29.0	26.0	22.0
Research and development	7.4	7.0	6.7	6.0	5.7
General and administrative	4.9	4.6	4.5	4.0
EBITA	6.1	6.5	5.1	3.1	-1.0
EBITA margin	13.9%	15.3%	12.6%	8.6%	-2.9%
Amortization of intangibles	0.7	0.9	1.0	1.0
EBIT	5.5	5.5	4.1	2.1	-1.0
EBIT margin	12.3%	13.1%	10.2%	5.9%	-2.9%
Pre-tax income	5.4	5.5	3.9	2.2	-1.0
Income taxes	0.6	1.8	1.3	0.7	-0.9
Tax rate	10.5%	32.3%	33.7%	29.6%	96.9%
Net income	4.9	3.7	2.6	1.5	-0.1
Net margin	11.0%	8.8%	6.3%	4.3%	-0.2%

Diluted EPS	$0.49	$0.40	$0.27	$0.17	($8.08)
Shares outstanding (diluted)	9.8	9.3	9.3	9.0	0.0

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.